Surendra Dasari,Michael R. McCarthy,Antonina A. Wojcik,Beth A. Pitel,Arpan Samaddar,Burak Tekin,Rumeal D. Whaley,Aditya Raghunathan,Loren Herrera Hernandez,Rafael E. Jimenez,Brad J. Stish,R. Houston Thompson,Bradley C. Leibovich,Stephen A. Boorjian,R. Jeffrey Karnes,Daniel S. Childs,J. Fernando Quevedo,Eugene D. Kwon,Lance C. Pagliaro,Brian A. Costello,Kevin C. Halling,John C. Cheville,Benjamin R. Kipp,Sounak Gupta

Abstract:Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC ( n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC ( n = 21), and mCR-PC ( n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.

Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients